EUCLID

Ticagrelor versus clopidogrel in symptomatic peripheral artery disease - New Engl J Med - 2017

Brief Summary:

In patients with symptomatic PAD, ticagrelor is not superior to clopidogrel with regard to the primary outcome of cardiovascular death, MI, or ischemic stroke. The rate of the primary outcome was very similar with either agent (10.6% with ticagrelor and 10.8% with clopidogrel) at median follow-up 30 months. The rate of major bleeding was 1.6% in each group.

Reference: http://www.ncbi.nlm.nih.gov/pubmed/27959717